Does MDGL pay a dividend and is it safe?

Madrigal Pharmaceuticals Inc. (MDGL) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / MDGL / dividends

SYRE (55) PTGX (65) TGTX (63) CORT (63) ⌘ Pro Terminal →

Madrigal Pharmaceuticals Inc. (MDGL) Dividend Safety Gauge & 10-Year DRIP Compounder

$431.16 +0.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $430.49

Madrigal Pharmaceuticals Inc. (MDGL) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $9.94B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDGL Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MDGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $431.16 (+0.19% 1D, market cap $9.94B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, MDGL ranks #494 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MDGL compare to SYRE and PTGX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MDGL carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -29.7%. By comparison, SYRE (Spyre Therapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -20.0%, cap $10.08B) and PTGX (Protagonist Therapeutics Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC -16.7%, cap $9.37B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDGL?

▼

Per MDGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001157601), Madrigal Pharmaceuticals Inc. generated $958.4M in revenue (+432.1% YoY), -$288.3M in net income, and -$190.0M in free cash flow against $1.26B in total assets and $339.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $430.47 (-0.16%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MDGL)Realized 20D OHLCV Swing Band: ±6.8%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY MDGL SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (37% of score)

Altman Z-Score 7.65 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit4/20 pts (-16 pt drag)

Macro rate sensitivity & RSI-14 (30.1) create a -16 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$460.01-0.4% Next Q

Q2 (-2Q)

Grade D$457.96-5.9% Next Q

Q3 (-1Q)

Grade D$431.00+0% Next Q

Current

Grade D-$431.16-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MDGL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MDGL currently carries a cautious 38/100 (D-) rating due to Macro Regime Fit (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($493.72) and Max Pain ($452.72) forces dealer call-delta covering toward $645.75.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MDGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (15.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $40,809

Est. Year-10 Shareholder Yield: $245/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.5K

Yr 1

$13.2K

Yr 2

$15.2K

Yr 3

$17.6K

Yr 4

$20.2K

Yr 5

$23.3K

Yr 6

$26.8K

Yr 7

$30.8K

Yr 8

$35.5K

Yr 9

$40.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDGL)

✓Walkthrough of MDGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MDGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.87%🛡️ HOLDING TREND SUPPORT

2026-11-03O $431.7H $431.7L $430.4C $431.2VOL 251.7K

RES: $530.4SUP: $424.0SMA50: $493.7SMA200: $498.9

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MDGL Butterfly Map → + Track MDGL →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

17.8%/yr Implied 5Y Growth

vs. +432.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MDGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MDGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MDGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDGL)

Health Care Rank #494 of 1015 ⚔️ SYRE vs MDGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MDGL vs. SYRE, PTGX, TGTX, CORT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Madrigal Pharmaceuticals Inc. (MDGL) ranks #494 by composite RQD confidence (38/100, grade D-) and #111 by equity capitalization ($9.94B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. PTGX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with MDGL at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MDGL ACTIVE Madrigal Pharmaceuticals Inc.	D-	38/100	—	—	-29.7%	+0.19%	$9.94B	Benchmark Subject
SYRE Spyre Therapeutics Inc.	D+	55/100	—	—	-20.0%	-1.09%	$10.08B	/syre-vs-mdgl →
PTGX Protagonist Therapeutics Inc.	C	65/100	—	—	-16.7%	-3.78%	$9.37B	/ptgx-vs-mdgl →
TGTX TG Therapeutics Inc.	C	63/100	19.9x	83.7%	12.0%	-2.01%	$9.36B	/tgtx-vs-mdgl →
CORT Corcept Therapeutics Incorporated	C	63/100	93.2x	96.0%	4.8%	-0.81%	$8.77B	/cort-vs-mdgl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001157601 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Madrigal Pharmaceuticals Inc. (MDGL) reported GAAP revenue of $958.4M (+432.1% vs. FY2024 revenue of $180.1M , and -10.0% cumulative change since FY2023) , GAAP net income of -$288.3M, operating cash flow of -$189.6M, and free cash flow of -$190.0M (+58.4% YoY). On the balance sheet, MDGL closed FY2025 with $1.26B in total assets against $339.9M in total debt (Altman Z-Score: 7.65, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$958.4M	-$288.3M	-$189.6M	-$190.0M	$1.26B	$339.9M
FY2024 (FY)	2024-12-31	$180.1M	-$465.9M	-$455.6M	-$457.0M	$1.04B	$117.6M
FY2023 (FY)	2023-12-31	$1.07B	-$373.6M	-$324.2M	-$324.2M	$5.49B	$1.28B

3. MDGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MDGL compare to SYRE and PTGX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MDGL?

Where is MDGL trading relative to its 50-day, 200-day, and 52-week technical levels?

MDGL last traded at $431.16 (+0.19% on volume of 495,143 shares), positioning the stock -12.67% below its 50-day simple moving average ($493.72) and -13.58% below its 200-day simple moving average ($498.90). Across its 52-week range of $399.00 to $615.00, MDGL sits at the 14.9% percentile with a 14-day RSI of 30.1 (OVERSOLD (<32)) and an implied next-earnings move of ±6.8% ($401.84 to $460.48).

Direct Sub-Reports: MDGL RQD Cockpit MDGL 12M Forecast MDGL Earnings & Move MDGL Dividends & DRIP MDGL Insiders & 13F MDGL Whale Options MDGL Profit Sankey MDGL News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MDGL — Madrigal Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Madrigal Pharmaceuticals Inc. (MDGL) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $431.16 (+0.19% 1D, market capitalization $9.94B).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -29.7%, gross margin of —, operating margin of -31.3%, and free cash flow yield of -1.91%.
Whale 13F & Options Flow (5/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (14/20): Incorporates a 1.08x equity beta, Altman Z-Score of 7.65, Piotroski F-Score of 6/9, and Debt/Equity of 0.56x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Madrigal Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..0B. FY 2025 revenue was $958.4M, indicating a commercial-stage revenue base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Madrigal Pharmaceuticals Inc. (MDGL) reported $958.4M in annual revenue (up from $180.1M in FY2024, +432.1% YoY) and -$288.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.07B revenue, -$373.6M net income) through FY2025, MDGL scaled operating cash flow to -$189.6M and free cash flow to -$190.0M, backed by $1.26B in total assets against $339.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.91% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $399.00 – $615.00 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -31.3% operating margins and a 1.08x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MDGL carries a macro regime beta of 1.08 and gross margin of —.

Key Question #1: Can MDGL sustain or expand its -31.3% operating margin and -29.7% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $958.4M and free cash flow of -$190.0M, how will capital allocation balance growth reinvestment against $339.9M in total debt?
Key Question #3: How sensitive is MDGL's 24.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.08x)?

MDGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Madrigal Pharmaceuticals Inc. (MDGL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MDGL Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 1d ago

Is Rezdiffra’s Genetic-Risk Agnostic Data Reframing The Investment Case For Madrigal Pharmaceuticals (MDGL)?

Yahoo Finance report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

Seeking Alpha report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 1d ago

MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug

Stocktwits report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Investing.com • 1d ago

UBS raises Madrigal Pharmaceuticals stock price target on F4 trial outlook

Investing.com report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Madrigal Pharmaceuticals, Inc. Estimates – NASDAQ:MDGL

TradingView report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus

Yahoo Finance report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Madrigal Pharmaceuticals (MDGL) Stock Looks Undervalued After A Very Large Five Year Run

Simply Wall St report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocks Down Under • 2d ago

Madrigal Pharmaceuticals (NDQ:MDGL): It's Got The First Scalable Treatment for a Disease We Barely Diagnose!

Stocks Down Under report covering Madrigal Pharmaceuticals Inc. (MDGL) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDGL Bull vs. Bear Conversation Board — What's Your Call at $431.16?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDGL 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $559.47 (+30.0%)

📌 Pinned Debate

Forensic balance-sheet strength (Altman Z 7.65, Piotroski F 6/9, Debt/Equity 0.56) plus an analyst price-target raise on the F4 trial o

Here is why I am bullish on MDGL here at $430.36: Forensic balance-sheet strength (Altman Z 7.65, Piotroski F 6/9, Debt/Equity 0.56) plus an analyst price-target raise on the F4 trial outlook support the thesis despite weak cash flow.. Compare MDGL's -31.3% operating margin and -29.7% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $408.84 are getting bought.

SectorRotator 🐂 BULL

@FadeTheHype Fair point on 24.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $352.90 (-18.0%)

Spot @ $430.36

ROIC of -29.7%, FCF yield of -1.91%, and FY 2025 FCF of -$190.0M against $198.7M cash show the business is not self-funding while the s

ROIC of -29.7%, FCF yield of -1.91%, and FY 2025 FCF of -$190.0M against $198.7M cash show the business is not self-funding while the stock trades at a 24 forward P/E.. Look at the math on MDGL: paying 24.0x forward P/E for -29.7% ROIC and -31.3% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $378.72 before getting long.